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a  b  s  t  r  a  c  t
Polysaccharide-based  device  for oral  delivery  of heparin  (HP)  was  successfully  prepared.  Previously  syn-
thesized  N,N-dimethyl  chitosan  (DMC)  (86%  dimethylated  by 1H  NMR  spectroscopy)  was  complexed
with  HP by  mixing  HP  and  DMC  aqueous  solutions  (both  at pH  3.0).  The  polyelectrolyte  complex  (PEC)
obtention  was conﬁrmed  by  infrared  spectroscopy  (FTIR),  thermogravimetric  analysis  (TGA/DTG)  and
wide-angle  X-ray  scattering  (WAXS).  In vitro  controlled  release  assays  of  HP  from  PEC  were investigatedeywords:
,N-Dimethyl chitosan
eparin
olyelectrolyte complex
in the  simulated  intestinal  ﬂuid  (SIF)  and  simulated  gastric  ﬂuid  (SGF).  The  PEC  efﬁciently  protected  the
HP  in  SGF  condition  in which  HP  is degraded.  On  the  other  hand,  in SIF  PEC  promoted  the  releasing
of  80  ± 1.5%  of  loaded  HP.  The  promissory  results  indicated  that the  PEC  based  on  DMC/HP  presented
potential  as drug-carrier  matrix,  since  biological  activity  of  HP  was  improved  at pH close  to physiological
condition.. Introduction
Heparin (HP) is a linear biopolymer that consists of sulfated
-glucosamine units, joined in alternating sequence by (1,4)-
lycosidic linkages, to either d-glucuronic or l-iduronic acid [1,2].
P is an anionic polysaccharide that, at speciﬁc conditions of
H, could be used to form polyelectrolyte complexes (PECs) with
ationic polymers [3–5]. HP presents many applications in medical
nd pharmaceutical areas. It acts indirectly in the blood coagulation
echanism, stimulates cellular growth and has antibacterial effects
3–5]. However, low molecular weight heparin (LMWHP) does not
resent effective anticoagulant activity [6]. The administration of
P is performed by intravenous or subcutaneous routes for it does
ot exist an efﬁcient oral method, since HP degradation occurs in
he gastrointestinal tract (GIT) [7]. In addition, high molecular mass
nd low lipophilicity of HP, reduces its absorption on GIT epithelial
embrane cells [7]. GIT epithelium acts as a physical and chemical
arrier toward the absorption of proteins and peptides, restricting
he entry of macromolecules into systemic circulation [7].
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On the other hand, conventional methods of administration
(intravenous or subcutaneous routes) lead to side effects [2].
Heparin-induced thrombocytopenia (HIT), hemorrhage and osteo-
porosis are the adverse effects most commonly observed after HP
administration [8,9]. The HIT is deﬁned when the platelet count
decreases 50% in relation to the platelet count prior of HP treat-
ment [9]. Patients that receive high amounts of HP (15,000 to
30,000 IU kg−1 daily) in periods over six months can develop osteo-
porosis [10]. However, the mechanism by which the HP produces
the osteoporosis is uncertain. Studies have suggested that HP binds
to the calcium ions and prevents calciﬁcation [11]. Therefore, to
transpose these problems is essential developing an efﬁcient HP
delivery device by the oral route. Compared to the conventional
methods of administration, delivery of drugs via the oral route is
relatively simple and non-invasive [7]. In this case, medication can
be easily administered and also avoid the risk of blood infections
or injury associated to the conventional methods of administra-
tion. In addition, oral administration occurs with absence of needle
and consequently this administration method is preferred due to
its improved convenience and patient compliance [7,12].
Chitosan (CHT) is a polysaccharide obtained from partial
deacetylation of chitin. CHT appears as a promising biopolymer
having unmatched features, including biocompatibility, biodegrad-
ability and antimicrobial properties with potential application
in advanced materials varying from tumor cells recognition and
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ustained release of drugs [1,13,14]. CHT/polyanionic polymer PECs
re widely used as implant devices and as drugs release vehicles
15,16]. CHT uses are limited, although there are many studies on
he use of CHT as drug carriers. This fact occurs due to its low solu-
ility at pH 7.4 [14], reduced mucoadhesion and a poor membrane
ell permeation above pH 6.5 [1,17,18]. Combining or preparing
HT-derivatives is a rational pathway to overcome CHT solubility
estrictions generating new materials with wider applications than
hose presented by conventional CHT-based materials [19,20].
N,N,N-Trimethyl chitosan (TMC), the simplest form of quater-
ized CHT, has greater antimicrobial action, mucoadhesivity and
ermeability in relation to CHT and it is water soluble even at
H > 7 [1,17]. Follmann et al. [21] developed antimicrobial and anti-
dhesive TMC/HP ﬁlms by LbL on chemically modiﬁed polystyrene
ubstrates. According to reports, one can verify a diversity of
tudies and applications using CHT and/or CHT-derivatives, spe-
ially on controlled drug release ﬁelds [22–25]. TMC  has better
ucoadhesion property regarding CHT due to N-trimethylation of
mino groups that provides permanent positively charged sites
18,26]. Besides, the free rotation of the C-H bonds as well as the
ydrophobic nature of methyl groups increase the permeability and
ucoadhesivity of TMC-based materials on epithelial cells [18,26].
P degradation can be inhibited in GIT and permeation enhancer
n the intestinal epithelium can be achieved by new polymeric
ystems (hydrogels) with stimuli-responsive and mucoadhesive
roperties [7].
On the other hand, TMC/heparin (TMC/HP) PECs are not suit-
ble HP carrier at physiological pH. In vitro release studies showed
he TMC/HP complex only protects HP on gastric condition and
epresses drug release on physiological conditions [1,2]. TMC  has
-quaternized [ +N(CH3)3] groups that display permanent charges
t any pH. Therefore, the electrostatic interactions among such sites
ith COO− and with OSO3− groups of HP are permanent at pH
.4. So, the release of HP from TMC/HP complex is suppressed in this
ondition due to the N-quaternization of the amino groups [1,2].
N,N-Dimethyl chitosan (DMC) does not have N-trimethylated
roups in its backbone. In this case, controlled release systems
ased on DMC can be advantageous over TMC, considering the
lectrostatic interactions on DMC/HP PEC could be undone at physi-
logical pH, improving HP releasing. So, DMC/HP PEC can maintain
he HP structure when subjected to gastric condition and at the
ame time act as an efﬁcient vehicle for HP at pH close to physiologi-
al condition. This paper describes, for the ﬁrst time, the association
f DMC  with a system formed by a polyelectrolyte complex of
MC/HP at pH 3.0. The release studies of heparin (HP) from DMC/HP
omplex matrix was evaluated in simulated gastric ﬂuid (SGF) and
imulated intestinal ﬂuid (SIF).
. Materials and methods
.1. Materials
Chitosan (85% deacetylated; M¯w of 8.7 × 104 g mol−1) was pur-
hased from Golden-Shell Biochemical (China). Heparin sodium
M¯w , of 14 × 103 g mol−1) was kindly supplied by Kin Master
Brazil). Cellulose membrane (molecular weight cut off: 12 kDa)
sed for dialysis, was purchased from Sigma-Aldrich (Brazil). Other
eagents, such as sodium hydroxide, formaldehyde and formic acid
ere used as purchased without further puriﬁcation.
.2. Synthesis of N,N-dimethyl chitosan (DMC)N,N-Dimethyl chitosan was synthesized based on method
eported by Matins et al. [27], with some adaptations. Initially, 10 g
f CHT, 30 mL  of formic acid, 40 mL  of formaldehyde and 180 mLgical Macromolecules 75 (2015) 186–191 187
of distilled water were added to a 500 mL  one neck round ﬂask.
The system was  kept under reﬂux at 70 ◦C for 120 h under mag-
netic stirring, and a yellow viscous solution was  obtained. The
yielded material was precipitated in NaOH solution (1.0 mol  L−1),
and the formation of a gel was observed. The gel was washed with
deionized water to remove the impurities and then dissolved in
dilute aqueous HCl solution (pH ≈ 4.0). This solution was dialyzed
against deionized water for ﬁve days and the DMC was frozen and
lyophilized.
2.3. Preparation of polyelectrolyte complex of DMC/HP
PEC was  obtained at pH 3.0 and the volume ratio of DMC-
solution to HP-solution was kept constant. The following procedure
was adopted: stock aqueous solutions of DMC (2.0 g in 200 mL  of
acetic acid/sodium acetate buffer solution) and HP (4.0 g in 200 mL
of acetic acid/sodium acetate buffer solution) were prepared. After-
ward, 20 mL  of the previously DMC-solution (1.0% w/v) was slowly
dropped into HP-solution (20 mL,  2.0% w/v) at room tempera-
ture and under magnetic stirring, keeping the volume ratio at
1/1 (DMC-solution/HP-solution). The formed material was washed
with deionized water and separated by centrifugation (30 min,
9500 rpm at 2.0 ◦C). Then, the precipitate was  washed with distilled
water, frozen and lyophilized at −55 ◦C for 48 h.
2.4. Characterization
2.4.1. 1H nuclear magnetic resonance spectroscopy
1H NMR  spectra were performed on a Varian, Mercury Plus
300 BB NMR  spectrometer (USA), operating at 300 MHz  for 1H fre-
quency. For the acquisition of 1H NMR  spectra, 10 mg  of CHT or
DMC  were dissolved in 1.0 mL  of D2O/CD3COOD (100/1 v/v). Spec-
tra were acquired at room temperature, and the main acquisition
parameters were as follows: a pulse of 45◦; a recycle delay of 10 s
and acquisition of 128 transients. Time-domain data were apodized
with a 0.2 Hz exponential function (lb) to improve the signal-
to-noise ratio before Fourier transformation. The dimethylation
degree (DD) of DMC  was determinate through 1H NMR  spectrum.
The result was obtained using the equation below [28].
DD% = [(CH3)2]
6[H2]
× 100 (1)
where [(CH3)2] is the integral of N-dimethylated amine groups at
3.10 ppm; [H2] is the integral of the H2 at 3.43 ppm, signal related
to the hydrogen atoms bound to the C2 of the DMC  molecule (see
DMC 1H NMR  spectrum in Fig. 1b).
2.4.2. FTIR spectroscopy
FTIR was used to characterize the chemical structure of mate-
rials (DMC, HP and PEC). In each case, KBr disk with 1.0 wt% of
the sample was prepared. The equipment from Shimadzu Scientiﬁc
Instruments (Model 8300, Japan) was used at the following condi-
tions: range of 4000–500 cm−1, resolution of 4 cm−1 obtained after
cumulating 64 scans.
2.4.3. Wide angle X-ray scattering (WAXS)
WAXS proﬁles were recorded on a Shimadzu diffractometer
model XRD-600 equipped with a Ni-ﬁltered Cu-K radiation. WAXS
proﬁles were collected in a scattering range of 2 = 5 to 70◦, with
a resolution of 0.02◦, at a scanning speed of 2◦ min−1. Analyzes
were performed by applying an accelerating voltage of 40 kV and a
current intensity of 30 mA.2.4.4. Thermogravimetric analysis (TGA)
TGA analysis were carried out on a thermogravimetric analyzer
(Netzsch, model STA 409PG/4/G Luxx, USA) at 10 ◦C min−1 rate
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nder nitrogen atmosphere with ﬂow rate of 20 mL  min−1, tem-
erature ranged from 25 to 800 ◦C.
.4.5. In vitro heparin release
In vitro heparin (HP) release studies were performed in two
ifferent environments, both without the presence of enzymes:
imulated intestinal ﬂuid (SIF, 6.8 g of KH2PO4 and 77 mL  aqueous
aOH 0.20 mol  L−1 in 1000 mL  of water, pH = 6.8); and simulated
astric ﬂuid (SGF, 2.0 g NaCl and 7.0 mL  of concentrated aqueous
olution of HCl 37% (v/v) in 1000 mL  of water, pH = 1.2) [2]. The
eleasing studies were carried out in a dissolutor apparatus Ethik
echnology, model 299-6TS. For each run, 400 mg  of dried PEC was
eposited in a sealed ﬂask with 400 mL  of SIF or SGF. For each con-
ition, the release study was carried out in duplicate (n = 2). So,
ach sample was kept under mild mechanical stirring (50 rpm), at
6.5 ◦C. At a desired time interval, an aliquot of 400 L was  removed
rom the ﬂask and directly added to 5.0 mL  of dimethyl-methylene
lue (DMB) solution (pH ≈ 3.0) [2] for quantifying the amount of
P released by UV measurements (Shimadzu, UV mini 1240) at
25 nm.  The absorbance related to DMB/heparin complex solution
ere performed immediately after homogenization of the system,
ccording to methodology described by Martins et al. [2]. To quan-
ify the solute released from PEC, one analytical curve (R2 = 0.999)
orrelating the absorption of DMB/HP complex to HP concentration
1.0 to 50.0 mg  L−1) using DMB  solution as solvent, was built.
. Results and discussion
1.1. Characterization of N,N-dimethyl chitosan by H NMR
All the 1H NMR  signals were attributed and related to the struc-
ures of polysaccharides (Scheme 1). The differences in the 1H NMR
Scheme 1. Synthetic route of DMC.Fig. 2. FTIR spectra of CHT, DMC, HP and PEC.
spectra indicate the DMC  was successfully obtained. The resonance
signal at ı 2.05 ppm presented in the CHT1H NMR  spectrum (Fig. 1a)
was assigned to the hydrogen atoms of acetylated residues; the res-
onance at ı 3.16 ppm was  assigned to the hydrogen atoms (H2); the
resonances observed between ı 3.61 and ı 4.45 ppm were assigned
to the hydrogen atoms (H3–H6) and resonances of low intensity
that occur in the spectral range between ı 4.5 and ı 5.5 ppm were
assigned to the hydrogen atoms (H1) [28–30]. However, the intense
resonance in the spectral range ı 4.72 to ı 5.00 was attributed to
hydrogen resonance of water molecules. DMC was  obtained with
dimethylation degree (DD) of ca. 86% [30,31]. The DD was obtained
using Eq (1), from the area attributed to resonance of hydrogen
atoms on N-dimethylated sites N(CH3)2, at ı 3.10 ppm, and from
area of H2 resonance at ı 3.43 ppm (Fig. 1b). The high value of DD
for DMC  (DD = 86%) conﬁrmed the fully N-dimethylation of NH2
groups of CHT since the acetylation degree of the CHT is ca. 15%.
3.2. Characterization of PECs by FTIR spectroscopy
FTIR spectra of CHT, DMC, HP and PEC (DMC/HP) are shown in
Fig. 2. The absorption that appears at 1600 cm−1 refers to angular
deformation of the N H bonds (Fig. 2a). The absorption at 1661 and
1320 cm−1 are characteristic of CHT and were assigned to amide I
and III, respectively [32,33]. The band at 1477 cm−1 was attributed
to angular deformation of C H bonds of methyl groups on DMC
structure, which occurred due to methylation of CHT (Fig. 1b) [33].
The bands at 1630 cm−1 and 1428 cm−1 in the HP FTIR spectrum
are assigned to the asymmetric and symmetric axial deformations
of the carboxylate anion ( COO−) [2]. When compared to the FTIR
spectrum of PEC, these bands have some changes due to complexa-
tion among HP and DMC  chains. In the HP FTIR spectrum the bands
at 1238 and 807 cm−1 were assigned to asymmetric axial deforma-
tion of the S O bonds and the axial deformation of C O S bonds,
respectively [2]. The band at 1740 cm−1 on PEC FTIR spectrum was
attributed to the C O bonds of carboxylic groups. HP is an anionic
biopolymer that consists of (1,4)-glycosidic linkages, to either
d-glucuronic and l-iduronic acid. The pKa values of d-glucuronic,
l-iduronic acid units are ca. 2.93 and 3.13, respectively [34]. There-
fore, some of the carboxyl groups of HP on PEC structure remain
non-ionized, since the PEC was obtained at pH 3.0. Therefore, the
band at 1740 cm−1 conﬁrms the DMC/HP PEC formation. On the
other hand, the band at 1740 cm−1 on HP FTIR spectrum did not
observe, whereas the raw HP was obtained as heparin sodium salt.
In this case, carboxylate groups on heparin sodium salt structure are
P.V.A. Bueno et al. / International Journal of Biological Macromolecules 75 (2015) 186–191 189
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onized. In addition, the PEC was obtained at pH 3.0 and this condi-
ion OSO3− groups on HP backbone are ionized, whereas OSO3H
Ka value is ca. 2.6 [35]. Therefore, the most likely structure of
MC/HP is depicted in Scheme 2.
.3. WAXS analysis
CHT WAXS proﬁle (curve Fig. 3a) exhibited diffraction peaks at
 = 6.9◦, 12.3◦, 19.1◦, 21.3◦, and 26.4◦. These crystalline domains
ccur due to high intensities of intermolecular H-bonds among
ydroxyl and amino groups on CHT chain segments [36]. DMC
AXS proﬁle (curve b) showed two broad peaks of low inten-
ity at 2 = 8.6◦ and 20◦. The insertion of methylic groups on CHT
ecreased the amount of intramolecular (DMC–DMC) H-bonds and,
onsequently, the DMC  crystallinity was reduced as well as the
rystalline structure that remained was changed, possibly due
o PEC chains self-assembly. The absence of diffraction peaks at
 = 6.9◦ and 12.3◦ (curve b) occurs due to full N-dimethylation of
he amino groups on CHT [37]. HP WAXS proﬁle (curve c) presented
 broad peak of low intensity in the 2 = 15◦–30◦ range. On the other
and, the PEC WAXS proﬁle (curve d) showed two  diffraction peaks
Fig. 4. TGA curves of CHT, DMC, HP and PEC (a)Fig. 3. WAXS proﬁles of CHT (a), DMC  (b), HP (c) and PEC (d).
at 2 = 11.4◦ and 20.3◦. The PEC was  obtained from separately DMC
and HP buffered solutions (at pH 3.0). This condition favors the
association among DMC +NH(CH3)2 groups with the HP anionic
sites, such as COO− and OSO3− groups. These interactions pro-
moted changes in the WAXS proﬁles, slightly increasing the PEC
crystallinity, regarding unmodiﬁed HP and DMC.
3.4. TGA analysis
TGA curves of CHT, DMC, HP and PEC are shown in Fig. 4a. The
ﬁrst event of weight loss occurred in the 30–100 ◦C range, and it
was attributed to evaporation of water and volatile compounds.
All the samples presented similar amounts of adsorbed water (10
to 15 wt%). The second event of weight loss occurred between 200
and 350 ◦C and was attributed to the polysaccharides degradation
(Fig. 4a). It was found that the CHT and HP are more thermally
stable when compared to the PEC and DMC  (Fig. 4a). The lower
thermal stability of such samples comparing to CHT and HP occurs
due to the high dimethylation content on CHT, i.e., due to inser-
tion of methyl groups on CHT. The inclusion of these hydrophobic
bulky groups (methyl groups) on CHT decreased the occurrence of
 and DTG curves of DMC, HP and PEC (b).
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value obtained was  0.015 min−1 (R2 = 0.93). Table 1 presents the
values of kr and R2 obtained from the curve shown in Fig. 5a, per-
formed in SIF, after apply Eqs. (3) and (4).
Table 1
Values of kr and R2 determined by the application of mathematical models described
through Eqs. (3) and (4) from releasing curve of heparin (Fig. 5a) obtained in SIF (pH
6.8) at 37 ◦C.ig. 5. Amount released of HP from PEC in SIF and SGF (Fig. 5a). Experimental and 
2) and (4) at 37 ◦C in SIF (Fig. 5b).
-bonds among DMC–DMC chains, comparing to CHT–CHT seg-
ents [1,33]. The ﬁrst derivatives of degradation stage (second
vent on TGA curves) for HP, DMC  and PEC are presented in Fig. 4b.
MC/HP sample showed two degradation temperatures, as indi-
ated by the inﬂexion points at 250 and 279 ◦C (Fig. 4b) which are
lightly higher than those observed for pure DMC  (235 ◦C) and pure
P (270 ◦C). This fact conﬁrms the PEC was obtained considering
hat the HP–DMC interactions provided higher thermal stability to
he complex.
.5. In vitro heparin release from PEC
HP releasing curves were obtained in SIF and SGF (Fig. 5a). The
aximum fraction of HP released in SIF (at pH 6.8) was  ca. 80 ± 1%,
.e., about 60 g of HP per each milligram of PEC (60 g mg−1).
he equilibrium state was  achieved after 250 min  (Fig. 5a). In SGF
edium (at pH 1.2), the fraction of HP released was lower than 5%
Fig. 5a), indicating that such PEC has potential to be used as a HP
ral delivery device. PEC was obtained at pH 3.0 because at this
ondition the N(CH3)2 groups are protonated [ +NH(CH3)2] and
an interact with HP anionic groups ( COO− and OSO3−) [34]. In
IF (pH 6.8) the N(CH3)2 groups did not protonate because the
Ka of these sites is around 6.5 [2,6]. Therefore, HP can be easily
eleased from PEC when the pH is equal or above 6.8. The N(CH3)2
ites are deprotonated in SIF and an amount of HP previously com-
lexed with DMC  molecules was released. On the other hand, in
GF (pH 1.2), the N(CH3)2 sites are ionized +NH(CH3)2, and the
lectrostatic interactions between DMC  and HP prevail. This fact
igniﬁcantly reduces the amount of HP released.
The release and absorption rates of HP are correspondents when
he condition of equilibrium is reached and the fractional release
Fr) attains a maximum value (Fmax) for a given condition (Fig. 5a)
37,38]. The solute distribution between the hydrogel 3D matrix
nd he external ﬂuid is deﬁned by the  ˛ parameter (partition
ctivity), which can be used to evaluate the partition phenomena
ccurrence. In this case,  ˛ parameter should reach a constant value
t the equilibrium state and can be determined from the Fmax value
y the following equation [38]: = Fmax
1 − Fmax (2)
The physical and chemical afﬁnity among solute, hydrogel
atrix and external ﬂuid is expressed by the  ˛ parameter. Thetical release proﬁles for HP obtained from mathematical models described by Eqs.
solute diffusion from hydrogel into external ﬂuid occurs when
 > 0 [38]. So, the amount of HP released from hydrogel could be
treated as a diffusion and/or partition phenomenon, because the ˛
value was  1.27, considering Fmax = 0.559 [37–39]. In this case, Fmax
and Fr parameters were obtained from release curve performed in
SIF (pH 6.8), being the Fmax = 0.559 for the ﬁrst 150 min  of assay
in SIF (Fig. 5a). Then, the kinetic constant of release (kr) could
be determined, using the partition–diffusion mathematical model
described by the following equations [38,39]:
Fmax ln
(
Fmax
Fmax − Fr
)
= krt (3)
˛
2
ln
(
Fr − 2Fr Fmax + Fmax
Fmax + Fr
)
= krt (4)
In this case, the solute fraction released, Fr, in a given release
time t, related to the ﬁrst order reversible kinetic can be determined
by Eq. (3), but if the release occurs through a second order reversible
kinetic, Eq. (4) can be used to establish the Fr value [38]. So, the
proposed models, described by Eqs. (3) and (4) were adjusted to
the experimental data for the ﬁrst 150 min  of assay in SIF, where
Fmax reached 0.559 (Fig. 5b).
The curves obtained by the application of Eqs. (3) and (4)
were superimposed to obtained experimental data, and the release
kinetic in SIF was  analyzed in the ﬁrst 150 min  of study (Fig. 5b).
The value of kr constant obtained was 0.075 min−1 (R2 = 0.99) and
the data described by Eq. (2) are in accordance with the experimen-
tal curve in SIF (Fig. 5a). Therefore, the experimental HP releasing
proﬁle is better explained by the ﬁrst-order kinetic model, because
when the second-order kinetic model was  applied the kr constantModel kr (min−1) R2
Eq. (3) 0.075 0.99
Eq. (4) 0.015 0.93
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. Conclusions
N,N-Dimethyl chitosan (DMC) was synthesized by methylation
f chitosan (CHT) and the degree of dimethylation was determinate
y 1H NMR. Polyelectrolyte complex of DMC/heparin (DMC/HP)
as obtained at pH 3.0. The materials were characterized by FTIR,
AXS and TGA/DTG analysis. Studies of controlled release of HP
ere performed on different environments (SGF and SIF). The
esults were satisfactory, since that 80% of HP-loaded was released
n SIF (pH 6.8), after 250 min  of assay. The release proﬁle obtained
n SIF followed a kinetic of ﬁrst-order. This fact was  conﬁrmed by
he partition-diffusion mathematical model described by Eq. (2).
o, the PEC based on DMC/HP could release HP of high molecu-
ar weight (14,000 g mol−1) at pH close to physiological condition.
y present such performance; the PEC has potential for act as an
fﬁcient vehicle for HP drug-carrier.
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